Nofebran (Metamizole Sodium Monohydrate)

Metamizole sodium monohydrate works by inhibiting cyclooxygenase enzymes and modulating prostaglandin synthesis, which reduces the production of substances that cause pain and fever. The precise mechanism is not completely understood, but the net effect is analgesia and antipyresis.

The appropriate dose of Nofebran is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and renal function. Dosage regimens can vary, and patients should follow the prescriber’s instructions without deviation.

Safety data for Metamizole sodium monohydrate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks with their healthcare provider before using Nofebran.

To order Nofebran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with traditional NSAIDs, Metamizole offers strong analgesic and antipyretic effects with a lower incidence of gastrointestinal irritation. Unlike opioids, it does not cause respiratory depression, but it carries a risk of rare blood‑cell disorders such as agranulocytosis, which requires monitoring.

Nofebran should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Nofebran is administered orally. The tablet or oral formulation should be swallowed whole with a glass of water, unless the prescriber provides specific instructions for crushing or mixing with food or liquid.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe skin reactions such as Stevens‑Johnson syndrome. Early detection through regular blood‑count monitoring is essential to mitigate these rare but critical adverse events.

Nofebran should be avoided in individuals with known hypersensitivity to Metamizole or other pyrazolones, patients with a history of blood‑cell disorders, and those who have experienced severe skin reactions to similar medications. Consultation with a healthcare professional is required before initiating therapy.